Letrozole

As a rule, adverse reactions were mild or moderate and were mainly associated with suppression of estrogen synthesis. The incidence of adverse reactions is assessed as follows: occurring “very often” -> 10%, “common” -> 1 - <10%, “infrequently” ->0.1% - <1%, “rarely” -> 0, 01 - <0.1%, "very rare" - <0.01%, including individual messages.

Infectious and parasitic diseases: uncommon - urinary tract infections.

Benign, malignant and unspecified neoplasms (including cysts and polyps): uncommon - pain in the area of the tumor.

Disorders of the blood and lymphatic system: infrequently - leukopenia.

Immune system disorders: frequency unknown - anaphylactic reactions.

Metabolic and nutritional disorders: very often - hypercholesterolemia; often - anorexia, increased appetite.

Mental disorders: often - depression; infrequently - anxiety (including nervousness), irritability.

Nervous system disorders: often - headache, dizziness; uncommon - drowsiness, insomnia, memory impairment, sensory disturbances (including paresthesia, hypoesthesia), taste disturbances, episodes of cerebrovascular accidents, carpal tunnel syndrome.

Visual disorders: uncommon - cataracts, eye irritation, blurred vision.

Cardiac disorders: uncommon - palpitations*, tachycardia, coronary heart disease (including newly diagnosed or worsening existing angina, angina requiring surgical intervention, myocardial infarction, myocardial ischemia).

Vascular disorders: very often - paroxysmal sensations of heat (“hot flashes”); often - increased blood pressure (BP); uncommon - thrombophlebitis (including thrombophlebitis of superficial and deep veins); rarely - pulmonary embolism, arterial thrombosis, stroke.

Disorders of the respiratory system, chest and mediastinal organs: infrequently - dyspnea, cough.

Gastrointestinal disorders: often - nausea*, vomiting, dyspepsia, constipation, diarrhea, abdominal pain; infrequently - stomatitis, dry mouth.

Disorders of the liver and biliary tract: infrequently - increased activity of liver enzymes; very rarely - hepatitis.

Disorders of the skin and subcutaneous tissues: very often - increased sweating; often - alopecia, dry skin, rash (including erythematous, maculopapular, psoriasiform and vesicular); infrequently - skin itching, urticaria; frequency unknown - angioedema, Lyell's syndrome (toxic epidermal necrolysis), Stevens-Johnson syndrome (malignant polymorphic exudative erythema).

Musculoskeletal and connective tissue disorders: very often - arthralgia; often - myalgia, bone pain*, osteoporosis, bone fractures; infrequently - arthritis; frequency unknown - trigger finger syndrome.

Renal and urinary tract disorders: infrequently - frequent urination.

Disorders of the genital organs and mammary glands: often - vaginal bleeding; uncommon - vaginal discharge, vaginal dryness, pain in the mammary glands.

General disorders and disorders at the injection site: very often - increased fatigue (including asthenia and discomfort); often - peripheral edema; infrequently generalized edema, dry mucous membranes, thirst, fever.

Laboratory and instrumental data: often - increase in body weight; infrequently - weight loss.

* - adverse reactions detected in the metastatic period.

Selected adverse reactions

Adverse reactions from the heart

With adjuvant therapy with Letrozole for 5 years, compared with placebo therapy for 3 years, the following adverse reactions were noted: angina pectoris requiring surgical intervention occurred in 0.8% of cases and in 0.6% of cases, respectively; coronary heart disease (including newly diagnosed or worsening existing angina) - in 1.4% and 1.0% of cases, respectively; myocardial infarction - in 1.0% and 0.7% of cases, respectively; thromboembolic events - in 0.9% and 0.3% of cases, respectively; stroke/transient ischemic attack - in 1.5% and 0.8% of cases, respectively.

Adverse reactions from the musculoskeletal system and connective tissue

With adjuvant therapy with Letrozole for 5 years, compared with placebo therapy for 3 years, the following adverse reactions were observed: bone fractures - in 10.4% and 5.8% of cases, respectively; osteoporosis - in 12.2% and 6.4% of cases, respectively.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Effects of taking

A non-steroidal aromatase inhibitor has the following effects on the athlete’s body:

relieves negative side effects from estrogens, including acne, gynecomastia, fullness, subcutaneous fat deposits;
eliminates gynecomastia in any manifestations even at the initial stage of the course;
helps preserve muscle mass from catabolism after stopping the drug, which often happens when stopping steroids.

The use of Letrozole is advisable when taking a course of androgens and anabolic steroids.

Exemestane

Of the described triad of direct AIs, Exemestane is the only one of steroid origin (similar to androstenedione). Exemestane has neither estrogenic nor progestogenic effects, but it has slight androgenic activity and does not affect the secretion of cortisol or aldosterone. Like other AIs, it causes an increase in gonadotropic hormones (even when taken in small dosages).

In Sports it is used as a means to block estrogenic side effects; to combat emerging signs of gynecomastia, dosages of 25 mg per day are used, but prevention requires 12.5-25 mg every other day. The maximum concentration of the drug after administration appears 2 hours after administration; its absorption (unlike the previous two drugs) improves by 40% if taken after a meal.

How to take it correctly

Bodybuilders are recommended to take about 1-3 milligrams per day at absolutely any time. Daily consumption of even 100 micrograms can significantly slow down the effect of the aromatase enzyme. Recommended dosages should not be exceeded. Otherwise, the chance of developing negative consequences, especially a decrease in sexual desire, increases sharply.

The daily dose for each bodybuilder is always selected individually. It all depends on the experience, age of the athlete, duration of use of a non-steroidal aromatase inhibitor, but should not exceed the optimal 1-3 milligrams. A specialist will help you calculate the exact amount of the drug. It is recommended to consult a doctor before using any pharmaceuticals. Long-term use of the drug allows you to slightly adjust the regimen for taking this substance and use the drug not daily, but every other day.

Letrozole on PCT (post-cycle therapy)

The Letrozole course suggests using the drug in variable dosages. They can change quite a lot. During post-cycle therapy, the norm remains unchanged. It is recommended to take the standard 2.5 milligrams per day for a week or 10 days, and then reduce the dosage to 0.5 milligrams over the next two or three weeks.

Why is cabergoline needed in bodybuilding?

Athletes who take anabolic steroids often experience symptoms of gynecomastia. This is a serious disease caused by hormonal imbalance; it is expressed not only in the growth of the mammary glands, but is also manifested by the presence of lactation. In a man, when the nipple is squeezed, a small amount of fluid may be released. This symptom indicates hormonal imbalances. Usually this is an imbalance between estrogens, prolactin and medications. When symptoms appear, you need to adjust the dosage of anabolic steroids, and also use cabergoline if the concentration of prolactin increases.

Why do you need Proviron: during and after the course?

The drug Proviron is based on a substance called mesterolone. Therefore, its international name sounds like mesterolone. It is an androgen that is called a sex drug because its initial effect is on libido. Proviron is taken in tablets. If you decide to buy Proviron, then first of all you should get acquainted with the mechanism of its pharmacological action.

Structure of an article about AAS:

Androgen is common during replacement therapy. It shows high results in stimulating male secondary sexual characteristics - increased potency, good sexual desire, fast and high-quality erection. In addition, Proviron has anabolic properties, which has gained fame among bodybuilding athletes. For sports, it is interesting for the following effects: protein synthesis, muscle tissue growth, bone growth, stimulation of erythropoiesis.

Possible side effects

The drug may cause:

headache;
nausea;
joint pain;
increase in body temperature;
strong feeling of weakness;
baldness;
attacks of dizziness;
high pressure.

Such negative phenomena appear only when an athlete exceeds the recommended dosage of the drug. If you follow the instructions, there will be no side effects.

Anastrozole

It is one of the most used AIs in the practice of modern bodybuilding to suppress estrogen-related side effects due to the intake of AS. It is a third generation selective aromatase inhibitor. This anti-estrogen appeared on the pharmacological market relatively recently (in the mid-90s of the 20th century), for the treatment of receptor-positive disseminated breast cancer in women.

It is a very effective means for inhibiting aromatization (conversion into estrogens) of even high doses of AS (such as all types of testosterones, methyltestosterone, and in case of high sensitivity to estrogens - boldenone). However, the downside of blocking estrogen activity is an increase in LDL, which not only increases the risk of developing atherosclerosis leading to the development of cardiovascular pathologies, but also leads to an increase in the density of cell membranes, reducing the efficiency of AS molecules entering the cell, and the potential for gaining muscle mass is also reduced, since in the presence of estrogens, muscle mass increases faster and more. {banner_st-d-1}

This drug is used either in case of the first signs of gynecomastia (then take 1 mg per day until the symptoms appear to be suppressed) or as a prevention of possible estrogenic side effects (then 500 mcg every other day). Take before meals with the required amount of water, maximum concentration is achieved within 1-2 hours after consumption.